Baird lowered the firm’s price target on Geron to $4.50 from $5 and keeps an Outperform rating on the shares. The firm views the stock as particularly attractive to own near-term, as they believe it’s likely the upcoming FDA AdCom meeting will end with a favorable vote.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GERN: